A clinical briefing for providers on Jardiance availability in 2026, including supply status, prescribing implications, cost landscape, and patient tools.
As a prescriber, you've likely fielded calls from patients unable to fill their Jardiance (Empagliflozin) prescriptions. While Empagliflozin is not in a formal FDA-listed shortage, intermittent pharmacy-level stock-outs are a widespread reality in 2026. This article provides the clinical and logistical context you need to manage these situations effectively.
As of March 2026, Empagliflozin (Jardiance) is not listed on the FDA Drug Shortage Database or the ASHP shortage list. Boehringer Ingelheim continues to manufacture and distribute the product. However, demand-driven availability gaps at individual pharmacies are common, particularly in the following scenarios:
These are distribution-level stock-outs, not a manufacturing failure. The product remains available through the supply chain — the challenge is matching local demand with local inventory.
Understanding the regulatory timeline helps explain current demand pressures:
Each indication expansion has materially increased the prescribing population while supply remains a single-source brand product.
When patients report they cannot fill Empagliflozin, consider the following clinical strategies:
Other SGLT2 inhibitors share the same mechanism of action and may be appropriate substitutes:
When switching, note that dosing equivalencies are not 1:1. Adjust based on indication, renal function, and formulary considerations.
If the standalone Empagliflozin tablet is unavailable, consider whether a combination product aligns with the patient's existing regimen:
These may have different stock profiles and can solve both the availability and polypharmacy challenges simultaneously.
Switching within the SGLT2 class may trigger new prior authorization requirements depending on the patient's insurance plan. Factor in processing time (typically 24-72 hours) and have a bridge strategy ready — whether that's providing samples or a short-course prescription of an alternative.
Advise your clinical staff and patients to use the following strategies:
Cost remains a significant barrier for many patients. The current pricing context:
For uninsured or underinsured patients, the Boehringer Ingelheim Cares Foundation offers a Patient Assistance Program (PAP) that provides free Jardiance to qualifying individuals. Direct patients to 1-800-556-8317 or the Boehringer Ingelheim patient portal.
For a patient-facing resource on savings, refer to our article: How to Save Money on Jardiance in 2026. For a provider-specific guide on helping patients save, see our provider savings guide.
Several developments in 2026-2027 may ease the current availability and cost pressures:
Empagliflozin remains a cornerstone therapy for type 2 diabetes, heart failure, and chronic kidney disease. While formal shortages don't exist, the practical availability challenges are real and require proactive management. Use Medfinder for Providers to check stock, educate patients on alternative sources, and have within-class substitution strategies ready. Your patients are counting on continuity of care — and with the right tools, you can deliver it.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
